E.L. Kwak

1.5k total citations
31 papers, 1.2k citations indexed

About

E.L. Kwak is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, E.L. Kwak has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in E.L. Kwak's work include Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Genomics and Diagnostics (5 papers). E.L. Kwak is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer Genomics and Diagnostics (5 papers). E.L. Kwak collaborates with scholars based in United States, South Korea and Australia. E.L. Kwak's co-authors include Suzy V. Torti, Frank M. Torti, Benjamin Solomon, K B Myambo, Ravi Salgia, Shannon C. Miller, Anthony P. Young, Leo Miller, G M Ringold and Robert G. Maki and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Biochemical and Biophysical Research Communications.

In The Last Decade

E.L. Kwak

30 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E.L. Kwak United States	12	631	501	414	212	212	31	1.2k
Eugenio Villa Italy	14	676 1.1×	396 0.8×	215 0.5×	103 0.5×	157 0.7×	20	973
Hitoshi Kusaba Japan	24	946 1.5×	387 0.8×	772 1.9×	99 0.5×	206 1.0×	112	1.8k
Jan J. Koornstra Netherlands	18	524 0.8×	463 0.9×	413 1.0×	473 2.2×	170 0.8×	32	1.5k
Katharine Hazell Switzerland	12	491 0.8×	423 0.8×	904 2.2×	137 0.6×	196 0.9×	19	1.3k
Paul K. Stockman United Kingdom	21	935 1.5×	737 1.5×	807 1.9×	79 0.4×	146 0.7×	39	1.9k
V. Damiano Italy	15	796 1.3×	568 1.1×	502 1.2×	78 0.4×	181 0.9×	34	1.3k
Fabien Calvo France	7	345 0.5×	199 0.4×	761 1.8×	216 1.0×	418 2.0×	13	1.4k
Olaf Christensen United States	16	847 1.3×	321 0.6×	542 1.3×	103 0.5×	110 0.5×	25	1.5k
Lisa Rodríguez United States	12	615 1.0×	318 0.6×	287 0.7×	160 0.8×	250 1.2×	20	1.1k
Paul Conkling United States	22	1.2k 1.8×	656 1.3×	523 1.3×	80 0.4×	140 0.7×	97	1.7k

Countries citing papers authored by E.L. Kwak

Since Specialization

Citations

This map shows the geographic impact of E.L. Kwak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.L. Kwak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.L. Kwak more than expected).

Fields of papers citing papers by E.L. Kwak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.L. Kwak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.L. Kwak. The network helps show where E.L. Kwak may publish in the future.

Co-authorship network of co-authors of E.L. Kwak

This figure shows the co-authorship network connecting the top 25 collaborators of E.L. Kwak. A scholar is included among the top collaborators of E.L. Kwak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.L. Kwak. E.L. Kwak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kwak, E.L., et al.. (2025). Effectiveness of the Maeum Program in a Stabilization-Focused Psychological Intervention for Trauma Survivors. Psychiatry Investigation. 22(7). 741–747.

Kwak, E.L., et al.. (2021). Target‐mediated drug disposition modeling of an anti‐TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics. Journal of Thrombosis and Haemostasis. 19(6). 1425–1435. 11 indexed citations

Desai, Jayesh, Yong Sang Hong, T.W. Kim, et al.. (2016). Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). Annals of Oncology. 27. vi155–vi155. 5 indexed citations

Wo, Jennifer Y., Andrew X. Zhu, Erin McDonnell, et al.. (2015). Clinical and Molecular Predictors of Local Failure After SBRT for Liver Metastases: A Secondary Analysis of a Prospective Phase II Trial. International Journal of Radiation Oncology*Biology*Physics. 93(3). S111–S112. 2 indexed citations

Blaszkowsky, Lawrence S., David P. Ryan, Jackie Szymonifka, et al.. (2013). Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Annals of Oncology. 25(1). 121–126. 21 indexed citations

Shaw, Alice T., B.Y. Yeap, Benjamin Solomon, et al.. (2011). Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.. Journal of Clinical Oncology. 29(15_suppl). 7507–7507. 28 indexed citations

Gandhi, Leena, Antoine Hollebecque, E.L. Kwak, et al.. (2011). Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3027–3027. 11 indexed citations

Lennerz, Jochen K., E.L. Kwak, Stephen B. Fox, et al.. (2011). Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification.. Journal of Clinical Oncology. 29(15_suppl). 4130–4130. 6 indexed citations

Shaw, Alice T., B.Y. Yeap, Daniel B. Costa, et al.. (2010). Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer.. Journal of Clinical Oncology. 28(15_suppl). 7606–7606. 11 indexed citations

10.

Shapiro, Geoffrey I., Julian R. Molina, Johanna C. Bendell, et al.. (2010). 387 First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics. European Journal of Cancer Supplements. 8(7). 123–123. 3 indexed citations

11.

Kwak, E.L., Alice T. Shaw, D. Ross Camidge, et al.. (2010). Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(18_suppl). 3–3. 105 indexed citations

12.

Solomon, Benjamin, Yu Jeong Bang, D. Ross Camidge, et al.. (2010). 369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements. 8(7). 117–117. 10 indexed citations

13.

Hong, Theodore S., H.K. Tsai, John J. Coen, et al.. (2010). Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy.. Journal of Clinical Oncology. 28(15_suppl). 4144–4144. 7 indexed citations

14.

Souglakos, John, Juliet Philips, Sheeba Marwah, et al.. (2009). Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. British Journal of Cancer. 101(3). 465–472. 240 indexed citations

15.

Zhu, Andrew X., J. A. Meyerhardt, Lawrence S. Blaszkowsky, et al.. (2009). Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX). Journal of Clinical Oncology. 27(15_suppl). 4578–4578. 4 indexed citations

16.

Shapiro, Geoffrey I., E.L. Kwak, José Baselga, et al.. (2009). Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3500–3500. 36 indexed citations

17.

Kwak, E.L., Nadia Godin-Heymann, Lecia V. Sequist, et al.. (2006). Molecular targeted therapy of lung cancer. Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory). 2 indexed citations

18.

Haber, Daniel A., Daphne W. Bell, Raffaella Sordella, et al.. (2005). Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology. 70(0). 419–426. 86 indexed citations

19.

Tsuji, Yoshiaki, E.L. Kwak, Takanori Saika, Suzy V. Torti, & Frank M. Torti. (1993). Preferential repression of the H subunit of ferritin by adenovirus E1A in NIH-3T3 mouse fibroblasts.. Journal of Biological Chemistry. 268(10). 7270–7275. 41 indexed citations

20.

Torti, Suzy V., E.L. Kwak, Shannon C. Miller, et al.. (1988). The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene.. Journal of Biological Chemistry. 263(25). 12638–12644. 275 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact